Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.44 |
| ▸ | CBFB | Q13951 | 1/20 | 0.44 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2672619 | 0.92 | MMP8 (0.54) | EPHX2MMP8PPARAPPARGMAPT | |
| SCHEMBL25403051 | 0.89 | MMP8 (0.55) | EPHX2MMP8PPARAPPARGMAPT | |
| SCHEMBL2050344 | 0.87 | MMP8 (0.53) | MMP8PPARAPPARGMAPTALDH1A1 | |
| SCHEMBL5326604 | 0.87 | MMP8 (0.53) | MMP8PPARAPPARGMAPTLMNA | |
| SCHEMBL3773871 | 0.86 | SLC6A2 (0.52) | PPARAPPARGLMNAALDH1A1HTT | |
| SCHEMBL534033 | 0.86 | EPHX2 (0.49) | EPHX2MMP8PPARAPPARGMAPT | |
| SCHEMBL7696784 | 0.85 | ESR1 (0.51) | MMP8ALDH1A1TP53NPY1RNPY2R | |
| SCHEMBL15274695 | 0.85 | EPHX2 (0.49) | EPHX2MMP8PPARAPPARGMAPT | |
| SCHEMBL7057182 | 0.84 | EPHX2 (0.44) | EPHX2PPARAPPARGMAPTLMNA | |
| SCHEMBL15454448 | 0.84 | SLC6A2 (0.50) | PPARAPPARGLMNAALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0180745-A1 | Acylacetate and amidine intermediates for pyrimidone compounds, and their preparation | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1986-05-14 | — | — | EP | claimed |
| US-11851435-B2 | PTGR2 inhibitors and their use | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-12-26 | — | — | US | disclosed |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-09-07 | — | — | US | disclosed |
| CN-116287032-A | Method for preparing 3-oxo-ethyl butyrate derivative by reacting aromatic aldehyde with ethyl acetoacetate under enzyme catalysis | 岭南师范学院 | 2023-06-23 | — | — | CN | disclosed |
| US-20210163489-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2021-06-03 | — | — | US | disclosed |
| US-20210163489-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2021-06-03 | — | — | US | disclosed |
| US-20200317674-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | An2H Discovery Limited (IE) | 2020-10-08 | — | — | US | disclosed |
| US-20200317674-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | An2H Discovery Limited (IE) | 2020-10-08 | — | — | US | disclosed |
| WO-2017210678-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | An2H Discovery Limited (IE) | 2017-12-07 | — | — | WO | disclosed |
| US-9212169-B2 | Benzimidazole derivative and use thereof | HYOGO COLLEGE OF MEDICINE (JP) | 2015-12-15 | — | — | US | disclosed |
| US-6538022-B1 | Three-dimensional structure of the cytosolic domain of phospholamban (PLB) and its active site from NMR data of sufficiently high resolution for the three-dimensional structure determination. rational drug design enabling the | ORION CORPORATION (FI) | 2003-03-25 | — | — | US | disclosed |
| EP-1039884-B1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORP (FI) | 2002-09-18 | — | — | EP | disclosed |
| US-6265421-B1 | DILATATION OF ARTERIES | ORION CORPORATION (FI) | 2001-07-24 | — | — | US | disclosed |
| EP-1039884-A1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORPORATION (FI) | 2000-10-04 | — | — | EP | disclosed |
| EP-1017691-A1 | BISETHERS OF 1-OXA, AZA AND THIANAPHTHALEN-2-ONES AS PHOSPHOLAMBAN INHIBITORS | ORION CORPORATION (ORION-YHTYMA OY) (FI) | 2000-07-12 | — | — | EP | disclosed |
| EP-1001774-A1 | USE OF PHOSPHOLAMBAN INHIBITORS TO INCREASING CORONARY FLOW | ORION CORPORATION (FI) | 2000-05-24 | — | — | EP | disclosed |
| US-5968959-A | ADMINISTERING PHOSPHOLAMBAN INHIBITOR | ORION CORPORATION (FI) | 1999-10-19 | — | — | US | disclosed |
| WO-1999030696-A1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORPORATION (FI) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999015523-A1 | BISETHERS OF 1-OXA, AZA AND THIANAPHTHALEN-2-ONES AS PHOSPHOLAMBAN INHIBITORS | ORION CORPORATION (FI) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999000132-A1 | USE OF PHOSPHOLAMBAN INHIBITORS FOR INCREASING CORONARY FLOW | ORION CORPORATION (FI) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317674-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | PINK1, ADRM1, LRRK2 | EPHX2 3239/4885MMP8 2965/4885PPARA 2066/4885 |
| US-11851435-B2 | PTGR2 inhibitors and their use | PTGFR, PTGIR, PTGDR2 | EPHX2 428/4885MMP8 1671/4885PPARA 494/4885 |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | PTGFR, PTGIR, PTGDR2 | EPHX2 428/4885MMP8 1671/4885PPARA 494/4885 |
| US-20210163489-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | PINK1, ADRM1, LRRK2 | EPHX2 3239/4885MMP8 2965/4885PPARA 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.